Table 4 Regression analysis of MYC expression and clinico-pathological variables
From: MYC amplification in subtypes of breast cancers in African American women
C-MYC Amplification | Odds | 95% CI | ||||||
|---|---|---|---|---|---|---|---|---|
< 2 | > 2 | Ratio | Lower | Upper | p-value | |||
Breast Cancer Molecular Subtype | ||||||||
Luminal A | 17 | 81.0% | 4 | 19.0% | ref. | |||
Luminal B | 4 | 28.6% | 10 | 71.4% | 10.63 | 2.16 | 52.15 | < 0.0001 |
HER 2+ | 1 | 12.5% | 7 | 87.5% | 29.75 | 2.80 | 315.56 | < 0.0001 |
Triple Negative Breast Cancer | 23 | 85.2% | 4 | 14.8% | 0.74 | 0.16 | 3.38 | 0.72 |
Estrogen Receptor Status | ||||||||
Positive | 21 | 60.0% | 14 | 40.0% | ref. | |||
Negative | 24 | 68.6% | 11 | 31.4% | 0.69 | 0.26 | 1.84 | 0.31 |
Progesterone Receptor Status | ||||||||
Positive | 21 | 65.6% | 11 | 34.4% | ref. | |||
Negative | 24 | 63.2% | 14 | 36.8% | 1.11 | 0.42 | 2.98 | 0.52 |
HER2 Status | ||||||||
Negative | 44 | 77.2% | 13 | 22.8% | ref. | |||
Positive | 1 | 7.7% | 12 | 92.3% | 40.62 | 4.82 | 342.39 | < 0.0001 |